clofibrate has been researched along with propranolol in 29 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 11 (37.93) | 18.7374 |
1990's | 1 (3.45) | 18.2507 |
2000's | 4 (13.79) | 29.6817 |
2010's | 13 (44.83) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Strassburg, CP; Tukey, RH | 1 |
Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Campillo, NE; Guerra, A; Páez, JA | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Chung, EK; Deglin, JM; Deglin, SM | 1 |
Mustard, JF; Packham, MA | 1 |
Glick, G; Pick, R | 1 |
Short, D | 1 |
Mehta, J; Mehta, P | 1 |
Weiss, HJ | 1 |
Blaton, V; Ferenczi, M; Lambelin, G; Peeters, H; Roba, J; Roncucci, R; Vandamme, D | 1 |
Haller, H; Hanefeld, M; Julius, U; Leonhardt, W | 1 |
Matthews, MB; Turck, WP | 1 |
DeMets, DL; Friedman, LM; Furberg, C; May, GS; Passamani, E | 1 |
Horwitz, RI; Horwitz, SM | 1 |
Dokianakis, SN; Kornaros, ME; Lyberatos, G | 1 |
7 review(s) available for clofibrate and propranolol
Article | Year |
---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug-induced cardiovascular diseases.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antidepressive Agents, Tricyclic; Antihypertensive Agents; Antipsychotic Agents; Cardiovascular Diseases; Clofibrate; Contraceptives, Oral; Cyclophosphamide; Digitalis Glycosides; Doxorubicin; Estrogens; Humans; Hypoglycemic Agents; Lithium; Methysergide; Narcotic Antagonists; Narcotics; Phenothiazines; Phenytoin; Procainamide; Propranolol; Quinidine; Sympathomimetics | 1977 |
Clinical pharmacology of platelets.
Topics: Adenosine Diphosphate; Aspirin; Blood Coagulation; Blood Platelets; Cell Membrane; Clofibrate; Cyproheptadine; Dipyridamole; Drug Therapy, Combination; Furosemide; Halofenate; Heparin; Humans; Hydrocortisone; Hydroxychloroquine; Methylprednisolone; Penicillin G; Platelet Aggregation; Propranolol; Prostaglandins; Sulfinpyrazone; Vitamin E | 1977 |
Drugs in the management of angina pectoris.
Topics: Aerosols; Amyl Nitrite; Angina Pectoris; Clofibrate; Delayed-Action Preparations; Humans; Nitroglycerin; Propranolol; Verapamil | 1969 |
The randomized clinical trial: bias in analysis.
Topics: Acute Disease; Alprenolol; Atenolol; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Humans; Myocardial Infarction; Patient Compliance; Placebos; Propranolol; Random Allocation; Sulfinpyrazone | 1981 |
Adherence to treatment and health outcomes.
Topics: Clofibrate; Double-Blind Method; Evaluation Studies as Topic; Humans; Hypercholesterolemia; Male; Myocardial Infarction; Patient Compliance; Propranolol; Randomized Controlled Trials as Topic; Treatment Outcome | 1993 |
1 trial(s) available for clofibrate and propranolol
Article | Year |
---|---|
The randomized clinical trial: bias in analysis.
Topics: Acute Disease; Alprenolol; Atenolol; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Humans; Myocardial Infarction; Patient Compliance; Placebos; Propranolol; Random Allocation; Sulfinpyrazone | 1981 |
22 other study(ies) available for clofibrate and propranolol
Article | Year |
---|---|
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Effects of propranolol, minoxidil, and clofibrate on cholesterol-induced atherosclerosis in stumptail macaques (Macaca arctoides).
Topics: Animals; Aorta; Arteriosclerosis; Cholesterol; Clofibrate; Coronary Disease; Coronary Vessels; Diet, Atherogenic; Disease Models, Animal; Haplorhini; Macaca; Male; Minoxidil; Propranolol; Pyrimidines | 1977 |
The management of the patient with angina.
Topics: Angina Pectoris; Anticoagulants; Clofibrate; Coronary Artery Bypass; Diazepam; Digoxin; Humans; Isosorbide Dinitrate; Nitroglycerin; Oxprenolol; Perhexiline; Prenylamine; Propranolol; Verapamil | 1977 |
Status of antiplatelet drugs in coronary heart disease.
Topics: Aspirin; Blood Platelets; Clofibrate; Coronary Disease; Dipyridamole; Humans; Male; Models, Biological; Platelet Aggregation; Propranolol; Sulfinpyrazone | 1979 |
Antiplatelet therapy (first of two parts).
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Blood Coagulation; Blood Platelets; Cell Survival; Clofibrate; Dextrans; Dipyridamole; Heparin; Humans; Platelet Adhesiveness; Platelet Aggregation; Propranolol; Rabbits; Sulfinpyrazone; Thrombosis | 1978 |
Potential antilipolytic activity of suloctidil.
Topics: Adipose Tissue; Animals; Clofibrate; Epididymis; Fatty Acids, Nonesterified; In Vitro Techniques; Male; Nicotinic Acids; Norepinephrine; Propanolamines; Propranolol; Rats; Theophylline | 1975 |
[Effect of propranolol and chlorophenoxybutyric acid (CPJB) on the dynamics of free fatty acids and blood sugar].
Topics: Blood Glucose; Clofibrate; Diabetes Mellitus; Fatty Acids, Nonesterified; Glucose; Humans; Middle Aged; Propranolol | 1972 |
Angina pectoris--II.
Topics: Adult; Aged; Angina Pectoris; Arrhythmias, Cardiac; Cholesterol; Cholestyramine Resin; Clofibrate; Diet; Female; Heart Failure; Humans; Hyperlipidemias; Hyperthyroidism; Male; Middle Aged; Myocardium; Oxygen Consumption; Pacemaker, Artificial; Propranolol; Warfarin | 1971 |
On the effect of pharmaceuticals on bacterial nitrite oxidation.
Topics: Bacteria, Anaerobic; Biodegradation, Environmental; Bioreactors; Carbamazepine; Cities; Clofibrate; Diclofenac; Drug-Related Side Effects and Adverse Reactions; Kinetics; Nitrites; Nitrogen; Ofloxacin; Oxidation-Reduction; Pharmaceutical Preparations; Propranolol; Sewage; Sulfamethoxazole; Triclosan; Waste Disposal, Fluid; Water Purification | 2004 |